Typhoid Fever 

Updated: Aug 19, 2019
Author: John L Brusch, MD, FACP; Chief Editor: Michael Stuart Bronze, MD 



Typhoid fever, also known as enteric fever, is a potentially fatal multisystemic illness caused primarily by Salmonella enterica serotype typhi and, to a lesser extent, S enterica serotypes paratyphi A, B, and C. The terms typhoid and enteric fever are commonly used to describe both major serotypes.

Typhoid fever has a wide variety of presentations that range from an overwhelming multisystemic illness to relatively minor cases of diarrhea with low-grade fever. The classic presentation is fever, malaise, diffuse abdominal pain, and constipation. Untreated typhoid fever may progress to delirium, obtundation, intestinal hemorrhage, bowel perforation, and death within 1 month of onset. Survivors may be left with long-term or permanent neuropsychiatric complications.

S typhi has been a major human pathogen for thousands of years, thriving in conditions of poor sanitation, crowding, and social chaos. It may have been responsible for the Great Plague of Athens at the end of the Pelopennesian War.[1] The name S typhi is derived from the ancient Greek typhos, an ethereal smoke or cloud that was believed to cause disease and madness. In the advanced stages of typhoid fever, the patient's level of consciousness is truly clouded. Although antibiotics have markedly reduced the frequency of typhoid fever in the developed world, it remains endemic in developing countries.[2] Infections with S paratyphi may be surpassing those caused by S typhi, in part because of immunological naivete among the population and incomplete coverage by vaccines that target typhi.

Note that some writers refer to the typhoid and paratyphoid fever as distinct syndromes caused by the typhi versus paratyphi serovars, while others use the term typhoid fever for a disease caused by either one. We use the latter terminology. We refer to these serovars collectively as typhoidal salmonella.


All pathogenic Salmonella species, when present in the gut are engulfed by phagocytic cells, which then pass them through the mucosa and present them to the macrophages in the lamina propria. Nontyphoidal salmonellae are phagocytized throughout the distal ileum and colon. With toll-like receptor (TLR)–5 and TLR-4/MD2/CD-14 complex, macrophages recognize pathogen-associated molecular patterns (PAMPs) such as flagella and lipopolysaccharides. Macrophages and intestinal epithelial cells then attract T cells and neutrophils with interleukin 8 (IL-8), causing inflammation and suppressing the infection.[3, 4]

In contrast to the nontyphoidal salmonellae, S typhi and paratyphi enter the host's system primarily through the distal ileum. They have specialized fimbriae that adhere to the epithelium over clusters of lymphoid tissue in the ileum (Peyer patches), the main relay point for macrophages traveling from the gut into the lymphatic system. The bacteria then induce their host macrophages to attract more macrophages.[3]

S typhi has a Vi capsular antigen that masks PAMPs, avoiding neutrophil-based inflammation, while the most common paratyphi serovar, paratyphi A, does not. This may explain the greater infectivity of typhi compared with most of its cousins.[5]

Typhoidal salmonella co-opt the macrophages' cellular machinery for their own reproduction[6] as they are carried through the mesenteric lymph nodes to the thoracic duct and the lymphatics and then through to the reticuloendothelial tissues of the liver, spleen, bone marrow, and lymph nodes. Once there, they pause and continue to multiply until some critical density is reached. Afterward, the bacteria induce macrophage apoptosis, breaking out into the bloodstream to invade the rest of the body.[4]

The bacteria then infect the gallbladder via either bacteremia or direct extension of infected bile. The result is that the organism re-enters the gastrointestinal tract in the bile and reinfects Peyer patches. Bacteria that do not reinfect the host are typically shed in the stool and are then available to infect other hosts.[2, 4] See the image below.

Life cycle of Salmonella typhi. Life cycle of Salmonella typhi.

Chronic carriers are responsible for much of the transmission of the organism. While asymptomatic, they may continue to shed bacteria in their stool for decades. The organisms sequester themselves either as a biofilm on gallstones or gallbladder epithelium or, perhaps, intracellularly, within the epithelium itself.[7] The bacteria excreted by a single carrier may have multiple genotypes, making it difficult to trace an outbreak to its origin.[8]

Risk factors

Typhoidal salmonella have no nonhuman vectors. An inoculum as small as 100,000 organisms of typhi causes infection in more than 50% of healthy volunteers.[9] Paratyphi requires a much higher inoculum to infect, and it is less endemic in rural areas. Hence, the patterns of transmission are slightly different.

The following are modes of transmission of typhoidal salmonella:

  • Oral transmission via food or beverages handled by an often asymptomatic individual—a carrier—who chronically sheds the bacteria through stool or, less commonly, urine

  • Hand-to-mouth transmission after using a contaminated toilet and neglecting hand hygiene

  • Oral transmission via sewage-contaminated water or shellfish (especially in the developing world).[10, 11, 12]

Paratyphi is more commonly transmitted in food from street vendors. It is believed that some such foods provide a friendly environment for the microbe.

Paratyphi is more common among newcomers to urban areas, probably because they tend to be immunologically naïve to it. Also, travellers get little or no protection against paratyphi from the current typhoid vaccines, all of which target typhi.[13, 14]

Typhoidal salmonella are able to survive a stomach pH as low as 1.5. Antacids, histamine-2 receptor antagonists (H2 blockers), proton pump inhibitors, gastrectomy, and achlorhydria decrease stomach acidity and facilitate S typhi infection.[4]

HIV/AIDS is clearly associated with an increased risk of nontyphoidal Salmonella infection; however, the data and opinions in the literature as to whether this is true for S typhi or paratyphi infection are conflicting. If an association exists, it is probably minor.[15, 16, 17, 18]

Other risk factors for typhoid fever include various genetic polymorphisms. These risk factors often also predispose to other intracellular pathogens. For instance, PARK2 and PACGR code for a protein aggregate that is essential for breaking down the bacterial signaling molecules that dampen the macrophage response. Polymorphisms in their shared regulatory region are found disproportionately in persons infected with Mycobacterium leprae and S typhi.[11]

On the other hand, protective host mutations also exist. The fimbriae of S typhi bind in vitro to cystic fibrosis transmembrane conductance receptor (CFTR), which is expressed on the gut membrane. Two to 5% of white persons are heterozygous for the CFTR mutation F508del, which is associated with a decreased susceptibility to typhoid fever, as well as to cholera and tuberculosis. The homozygous F508del mutation in CFTR is associated with cystic fibrosis. Thus, typhoid fever may contribute to evolutionary pressure that maintains a steady occurrence of cystic fibrosis, just as malaria maintains sickle cell disease in Africa.[19, 20]

As the middle class in south Asia grows, some hospitals there are seeing a large number of typhoid fever cases among relatively well-off university students who live in group households with poor hygiene.[21] American clinicians should keep this in mind, as students from these areas often come to the United States for further education.[22]



United States

Since 1900, improved sanitation and successful antibiotic treatment have steadily decreased the incidence of typhoid fever in the United States. In 1920, 35,994 cases of typhoid fever were reported. In 2006, there were 314.

Between 1999 and 2006, 79% of typhoid fever cases occurred in patients who had been outside of the country within the preceding 30 days. Two thirds of these individuals had just journeyed from the Indian subcontinent. The 3 known outbreaks of typhoid fever within the United States were traced to imported food or to a food handler from an endemic region. Remarkably, only 17% of cases acquired domestically were traced to a carrier.[23]


Typhoid fever occurs worldwide, primarily in developing nations whose sanitary conditions are poor. Typhoid fever is endemic in Asia, Africa, Latin America, the Caribbean, and Oceania, but 80% of cases come from Bangladesh, China, India, Indonesia, Laos, Nepal, Pakistan, or Vietnam.[24] Within those countries, typhoid fever is most common in underdeveloped areas. Typhoid fever infects roughly 21.6 million people (incidence of 3.6 per 1,000 population) and kills an estimated 200,000 people every year.[25]

In the United States, most cases of typhoid fever arise in international travelers. The average yearly incidence of typhoid fever per million travelers from 1999-2006 by county or region of departure was as follows:[23]

  • Western Hemisphere outside Canada/United States - 1.3

  • Africa - 7.6

  • Asia - 10.5

  • India - 89 (122 in 2006)

  • Total (for all countries except Canada/United States) - 2.2


With prompt and appropriate antibiotic therapy, typhoid fever is typically a short-term febrile illness requiring a median of 6 days of hospitalization. Treated, it has few long-term sequelae and a 0.2% risk of mortality.[23] Untreated typhoid fever is a life-threatening illness of several weeks' duration with long-term morbidity often involving the central nervous system. The case fatality rate in the United States in the pre-antibiotic era was 9%-13%.[26]


Typhoid fever has no racial predilection.


Fifty-four percent of typhoid fever cases in the United States reported between 1999 and 2006 involved males.[23]


Most documented typhoid fever cases involve school-aged children and young adults. However, the true incidence among very young children and infants is thought to be higher. The presentations in these age groups may be atypical, ranging from a mild febrile illness to severe convulsions, and the S typhi infection may go unrecognized. This may account for conflicting reports in the literature that this group has either a very high or a very low rate of morbidity and mortality.[21, 27]




A severe nonspecific febrile illness in a patient who has been exposed to typhoidal salmonella should always raise the diagnostic possibility of typhoid fever (enteric fever).

Classic typhoid fever syndrome

The clinical syndromes associated with S typhi and paratyphi are indistinguishable. Typhoid fever begins 7-14 days after ingestion of the organism . The fever pattern is stepwise, characterized by a rising temperature over the course of each day that drops by the subsequent morning. The peaks and troughs rise progressively over time.

Over the course of the first week of illness, the notorious gastrointestinal manifestations of the disease develop. These include diffuse abdominal pain and tenderness and, in some cases, fierce colicky right upper quadrant pain. Monocytic infiltration inflames Peyer patches and narrows the bowel lumen, causing constipation that lasts the duration of the illness. The individual then develops a dry cough, dull frontal headache, delirium, and an increasingly stuporous malaise.[2]

At approximately the end of the first week of illness, the fever plateaus at 103-104°F (39-40°C). The patient develops rose spots, which are salmon-colored, blanching, truncal, maculopapules usually 1-4 cm wide and fewer than 5 in number; these generally resolve within 2-5 days.[2] These are bacterial emboli to the dermis and occasionally develop in persons with shigellosis or nontyphoidal salmonellosis.[28]

During the second week of illness, the signs and symptoms listed above progress. The abdomen becomes distended, and soft splenomegaly is common. Relative bradycardia and dicrotic pulse (double beat, the second beat weaker than the first) may develop.

In the third week, the still febrile individual grows more toxic and anorexic with significant weight loss. The conjunctivae are infected, and the patient is tachypneic with a thready pulse and crackles over the lung bases. Abdominal distension is severe. Some patients experience foul, green-yellow, liquid diarrhea (pea soup diarrhea). The individual may descend into the typhoid state, which is characterized by apathy, confusion, and even psychosis. Necrotic Peyer patches may cause bowel perforation and peritonitis. This complication is often unheralded and may be masked by corticosteroids. At this point, overwhelming toxemia, myocarditis, or intestinal hemorrhage may cause death.

If the individual survives to the fourth week, the fever, mental state, and abdominal distension slowly improve over a few days. Intestinal and neurologic complications may still occur in surviving untreated individuals. Weight loss and debilitating weakness last months. Some survivors become asymptomatic S typhi carriers and have the potential to transmit the bacteria indefinitely.[21, 29, 30, 2, 4]

Various presentations of typhoid fever

The clinical course of a given individual with typhoid fever may deviate from the above description of classic disease. The timing of the symptoms and host response may vary based on geographic region, race factors, and the infecting bacterial strain. The stepladder fever pattern that was once the hallmark of typhoid fever now occurs in as few as 12% of cases. In most contemporary presentations of typhoid fever, the fever has a steady insidious onset.

Young children, individuals with AIDS, and one third of immunocompetent adults who develop typhoid fever develop diarrhea rather than constipation. In addition, in some localities, typhoid fever is generally more apt to cause diarrhea than constipation.

Atypical manifestations of typhoid fever include isolated severe headaches that may mimic meningitis, acute lobar pneumonia, isolated arthralgias, urinary symptoms, severe jaundice, or fever alone. Some patients, especially in India and Africa, present primarily with neurologic manifestations such as delirium or, in extremely rare cases, parkinsonian symptoms or Guillain-Barré syndrome. Other unusual complications include pancreatitis,[31] meningitis, orchitis, osteomyelitis, and abscesses anywhere on the body.[2]

Table 1. Incidence and Timing of Various Manifestations of Untreated Typhoid Fever [2, 32, 33, 34, 35, 36] (Open Table in a new window)



Week 1

Week 2

Week 3

Week 4



Recovery phase or death (15% of untreated cases)

10%-20% relapse; 3%-4% chronic carriers;

long-term neurologic sequelae (extremely rare);

gallbladder cancer (RR=167; carriers)

Stepladder fever pattern or insidious onset fever


Very commona

Very common

Acute high fever


Very rareb





Almost allc






Almost all



Very common




Almost all

Almost all

Typhoid state (common)




Very common




Very common



Very rare





Very rare



Frontal headache

(usually mild)


Very common



Meningeal signs







Very rare



Ear, nose, and throat

Coated tongue


Very common



Sore throatf






Mild cough





Bronchitic cough












Rare (lobar)





Dicrotic pulse











Extremely rareg







Very rare




Very common





Common (pea soup)

Bloating with tympany


Very common (84%)[36]



Diffuse mild abdominal pain


Very common



Sharp right lower quadrant pain





Gastrointestinal hemorrhage


Very rare; usually trace

Very common

intestinal perforation











Gallbladder pain


Very rare


Urinary retention






Renal pain





Very rare


Very rare


Arthritis (large joint)

Extremely rare


Rose spots




Abscess (anywhere)


Extremely rare

Extremely rare

Extremely rare

a Very common: Symptoms occur in well over half of cases (approximately 65%-95%).

b Very rare: Symptoms occur in less than 5% of cases.

c Almost all: Symptoms occur in almost all cases.

d Common: Symptoms occur in 35%-65% of cases.

e Rare: Symptoms occur in 5%-35% of cases.

f Blank cells: No mention of the symptom at that phase was found in the literature.

g Extremely rare: Symptoms have been described in occasional case reports.

Treated typhoid fever

If appropriate treatment is initiated within the first few days of full-blown illness, the disease begins to remit after about 2 days, and the patient's condition markedly improves within 4-5 days. Any delay in treatment increases the likelihood of complications and recovery time.


See History.


S typhi and Salmonella paratyphi cause typhoid/enteric fever.

Physical Examination

See History.


See History.



Differential Diagnoses



Laboratory Studies

The diagnosis of typhoid fever (enteric fever) is primarily clinical.

Importantly, the reported sensitivities of tests for S typhi vary greatly in the literature, even among the most recent articles and respected journals.


The criterion standard for diagnosis of typhoid fever has long been culture isolation of the organism. Cultures are widely considered 100% specific.

Culture of bone marrow aspirate is 90% sensitive until at least 5 days after commencement of antibiotics. However, this technique is extremely painful, which may outweigh its benefit.[37]

Blood, intestinal secretions (vomitus or duodenal aspirate), and stool culture results are positive for S typhi in approximately 85%-90% of patients with typhoid fever who present within the first week of onset. They decline to 20%-30% later in the disease course. In particular, stool culture may be positive for S typhi several days after ingestion of the bacteria secondary to inflammation of the intraluminal dendritic cells. Later in the illness, stool culture results are positive because of bacteria shed through the gallbladder.

Multiple blood cultures (>3) yield a sensitivity of 73%-97%. Large-volume (10-30 mL) blood culture and clot culture may increase the likelihood of detection.[38]

Stool culture alone yields a sensitivity of less than 50%, and urine culture alone is even less sensitive. Cultures of punch-biopsy samples of rose spots reportedly yield a sensitivity of 63% and may show positive results even after administration of antibiotics. A single rectal swab culture upon hospital admission can be expected to detect S typhi in 30%-40% of patients. S typhi has also been isolated from the cerebrospinal fluid, peritoneal fluid, mesenteric lymph nodes, resected intestine, pharynx, tonsils, abscess, and bone, among others.

Bone marrow aspiration and blood are cultured in a selective medium (eg, 10% aqueous oxgall) or a nutritious medium (eg, tryptic soy broth) and are incubated at 37°C for at least 7 days. Subcultures are made daily to one selective medium (eg, MacConkey agar) and one inhibitory medium (eg, Salmonella-Shigella agar). Identification of the organism with these conventional culture techniques usually takes 48-72 hours from acquisition.

Table 2. Sensitivities of Cultures [2, 38, 39, 40] (Open Table in a new window)



Week 1

Week 2

Week 3

Week 4

Bone marrow aspirate (0.5-1 mL)


90% (may decrease after 5 d of antibiotics)

Blood (10-30 mL), stool, or duodenal aspirate culture



Variable (20%-60%)



25%-30%, timing unpredictable

Polymerase chain reaction

Polymerase chain reaction (PCR) has been used for the diagnosis of typhoid fever with varying success. Nested PCR, which involves two rounds of PCR using two primers with different sequences within the H1-d flagellin gene of S typhi, offers the best sensitivity and specificity. Combining assays of blood and urine, this technique has achieved a sensitivity of 82.7% and reported specificity of 100%. However, no type of PCR is widely available for the clinical diagnosis of typhoid fever.[41, 42]

Specific serologic tests

Assays that identify Salmonella antibodies or antigens support the diagnosis of typhoid fever, but these results should be confirmed with cultures or DNA evidence.

The Widal test was the mainstay of typhoid fever diagnosis for decades. It is used to measure agglutinating antibodies against H and O antigens of S typhi. Neither sensitive nor specific, the Widal test is no longer an acceptable clinical method.

Indirect hemagglutination, indirect fluorescent Vi antibody, and indirect enzyme-linked immunosorbent assay (ELISA) for immunoglobulin M (IgM) and IgG antibodies to S typhi polysaccharide, as well as monoclonal antibodies against S typhi flagellin,[43] are promising, but the success rates of these assays vary greatly in the literature.

Other nonspecific laboratory studies

Since the sensitivity of cultures of blood, bone marrow, urine and stool vary with the duration of disease, various nonspecific tests have been studied regarding usefulness in diagnosing typhoid fever.

Most patients with typhoid fever are moderately anemic, have an elevated erythrocyte sedimentation rate (ESR), thrombocytopenia, and relative lymphopenia.

Most also have a slightly elevated prothrombin time (PT) and activated partial thromboplastin time (aPTT) and decreased fibrinogen levels.

Circulating fibrin degradation products commonly rise to levels seen in subclinical disseminated intravascular coagulation (DIC).

Liver transaminase and serum bilirubin values usually rise to twice the reference range.

Mild hyponatremia and hypokalemia are common.

A combination of absolute eosinopenia, elevated aspartate aminotransferase levels, and elevated C-reactive protein levels (>40 mg/L) have been shown to be a positive predictor of S typhi and S paratyphi bacteremia.[44]

A serum alanine amino transferase (ALT)–to–lactate dehydrogenase (LDH) ratio of more than 9:1 appears to be helpful in distinguishing typhoid from viral hepatitis. A ratio of greater than 9:1 supports a diagnosis of acute viral hepatitis, while ratio of less than 9:1 supports typhoid hepatitis.[45]

Imaging Studies

Radiography: Radiography of the kidneys, ureters, and bladder (KUB) is useful if bowel perforation (symptomatic or asymptomatic) is suspected.

CT scanning and MRI: These studies may be warranted to investigate for abscesses in the liver or bones, among other sites.


Bone marrow aspiration: The most sensitive method of isolating S typhi is BMA culture (see Lab Studies).

Histologic Findings

The hallmark histologic finding in typhoid fever is infiltration of tissues by macrophages (typhoid cells) that contain bacteria, erythrocytes, and degenerated lymphocytes. Aggregates of these macrophages are called typhoid nodules, which are found most commonly in the intestine, mesenteric lymph nodes, spleen, liver, and bone marrow but may be found in the kidneys, testes, and parotid glands. In the intestines, 4 classic pathologic stages occur in the course of infection: (1) hyperplastic changes, (2) necrosis of the intestinal mucosa, (3) sloughing of the mucosa, and (4) the development of ulcers. The ulcers may perforate into the peritoneal cavity.

In the mesenteric lymph nodes, the sinusoids are enlarged and distended by large collections of macrophages and reticuloendothelial cells. The spleen is enlarged, red, soft, and congested; its serosal surface may have a fibrinous exudate. Microscopically, the red pulp is congested and contains typhoid nodules. The gallbladder is hyperemic and may show evidence of cholecystitis. Liver biopsy specimens from patients with typhoid fever often show cloudy swelling, balloon degeneration with vacuolation of hepatocytes, moderate fatty change, and focal typhoid nodules. Intact typhoid bacilli can be observed at these sites.[2, 4]


The proper treatment approach to typhoid fever depends on whether the illness is complicated or uncomplicated. Complicated typhoid fever is characterized by melena (3% of all hospitalized patients with typhoid fever), serious abdominal discomfort, intestinal perforation, marked neuropsychiatric symptoms, or other severe manifestations. Depending on the adequacy of diagnosis and treatment, complicated disease may develop in up to 10% of treated patients. Delirium, obtundation, stupor, coma, or shock demands a particularly aggressive approach (see Treatment).[35]



Medical Care

If a patient presents with unexplained symptoms described in Table 1 within 60 days of returning from an typhoid fever (enteric fever) endemic area or following consumption of food prepared by an individual who is known to carry typhoid, broad-spectrum empiric antibiotics should be started immediately. Treatment should not be delayed for confirmatory tests since prompt treatment drastically reduces the risk of complications and fatalities. Antibiotic therapy should be narrowed once more information is available.

Compliant patients with uncomplicated disease may be treated on an outpatient basis. They must be advised to use strict handwashing techniques and to avoid preparing food for others during the illness course. Hospitalized patients should be placed in contact isolation during the acute phase of the infection. Feces and urine must be disposed of safely.

Surgical Care

Surgery is usually indicated in cases of intestinal perforation. Most surgeons prefer simple closure of the perforation with drainage of the peritoneum. Small-bowel resection is indicated for patients with multiple perforations.[46]

If antibiotic treatment fails to eradicate the hepatobiliary carriage, the gallbladder should be resected. Cholecystectomy is not always successful in eradicating the carrier state because of hepatic infection.


An infectious disease specialist should be consulted. Consultation with a surgeon is indicated upon suspected gastrointestinal perforation, serious gastrointestinal hemorrhage, cholecystitis, or extraintestinal complications (arteritis, endocarditis, organ abscesses).


Fluids and electrolytes should be monitored and replaced diligently. Oral nutrition with a soft digestible diet is preferable in the absence of abdominal distension or ileus.


No specific limitations on activity are indicated for patients with typhoid fever. As with most systemic diseases, rest is helpful, but mobility should be maintained if tolerable. The patient should be encouraged to stay home from work until recovery.




Class Summary

Definitive treatment of typhoid fever (enteric fever) is based on susceptibility. As a general principle of antimicrobial treatment, intermediate susceptibility should be regarded as equivalent to resistance. Between 1999 and 2006, 13% of S typhi isolates collected in the United States were multidrug resistant.

Until susceptibilities are determined, antibiotics should be empiric, for which there are various recommendations. The authors of this article recommend combination treatment with ceftriaxone and ciprofloxacin when neither the sensitivities nor the geographical origin of the bacteria is known.

The particular sensitivity pattern of the organism in its area of acquisition should be the major basis of empiric antibiotic choice. It may soon become necessary to treat all cases presumptively for multidrug resistance until sensitivities are obtained.

History of antibiotic resistance

Chloramphenicol was used universally to treat typhoid fever from 1948 until the 1970s, when widespread resistance occurred. Ampicillin and trimethoprim-sulfamethoxazole (TMP-SMZ) then became treatments of choice. However, in the late 1980s, some S typhi and S paratyphi strains (multidrug resistant [MDR] S typhi or S paratyphi) developed simultaneous plasmid-mediated resistance to all three of these agents.

Fluoroquinolones are highly effective against susceptible organisms, yielding a better cure rate than cephalosporins. Unfortunately, resistance to first-generation fluoroquinolones is widespread in many parts of Asia.

H58 type S typhi has become the predominant multidrug-resistant (MDR) isolate throughout Asia and Africa, 75% of all resistant strains.[47] However, MDR isolates can be very localized. Most isolates of S typhi and S paratyphi from Pakistan exhibited a high degree of multidrug resistance, while isolates from Bangladesh, India, and Nepal showed a low rate.[48]

In recent years, third-generation cephalosporins have been used in regions with high fluoroquinolone resistance rates, particularly in south Asia and Vietnam. Unfortunately, sporadic resistance has been reported, so it is expected that these will become less useful over time.[49]

Mechanisms of antibiotic resistance

The genes for antibiotic resistance in S typhi and S paratyphi are acquired from Escherichia coli and other gram-negative bacteria via plasmids. The plasmids contain cassettes of resistance genes that are incorporated into a region of the Salmonella genome called an integron. Some plasmids carry multiple cassettes and immediately confer resistance to multiple classes of antibiotics. This explains the sudden appearance of MDR strains of S typhi and S paratyphi, often without intermediate strains that have less-extensive resistance.

The initial strains of antibiotic-resistant S typhi and S paratyphi carried chloramphenicol acetyltransferase type I, which encodes an enzyme that inactivates chloramphenicol via acetylation. MDR strains may carry dihydrofolate reductase type VII, which confers resistance to trimethoprim. Interestingly, in areas where these drugs have fallen out of use, S typhi has reverted to wild type, and they are often more effective than newer agents.[50, 51, 52, 36]

Resistance to fluoroquinolones is evolving in an ominous direction. Fluoroquinolones target DNA gyrase and topoisomerase IV, bacterial enzymes that are part of a complex that uncoils and recoils bacterial DNA for transcription.[53] S typhi most commonly develops fluoroquinolone resistance through specific mutations in gyrA and parC, which code for the binding region of DNA gyrase and topoisomerase IV, respectively.

A single point mutation gyrA confers partial resistance. If a second gyrA point mutation is added, the resistance increases somewhat. However, a mutation in parC added to a single gyrA mutation confers full in vitro resistance to first-generation fluoroquinolones. Clinically, these resistant strains show a 36% failure rate when treated with a first-generation fluoroquinolone such as ciprofloxacin.[54] The risk of relapse after bacterial clearance is higher in both partially and fully resistant strains than in fully susceptible strains.[24]

The third-generation fluoroquinolone gatifloxacin appears to be highly effective against all known clinical strains of S typhi both in vitro and in vivo owing to its unique interface with gyrA. It achieves better results than cephalosporins even among strains that are considered fluoroquinolone resistant. However, gatifloxacin is no longer on the market in the United States, and its use cannot be generalized to any other member of the class.[55, 56]

In any case, as gatifloxacin replaces older fluoroquinolones in high-prevalence resistance is bound to emerge. Any two of a number of gyrA mutations, when added to the parC mutation, confer full in vitro resistance. Although such a combination has yet to be discovered in vivo, all of these mutations exist in various clinic strains, and it seems highly likely that a gatifloxacin-resistant one will be encountered clinically if selective pressure with fluoroquinolones continues to be exerted.[54]

Geography of resistance

Among S typhi isolates obtained in the United States between 1999 and 2006, 43% were resistant to at least one antibiotic.

Nearly half of S typhi isolates found in the United States now come from travelers to the Indian subcontinent, where fluoroquinolone resistance is endemic (see Table 3). The rate of fluoroquinolone resistance in south and Southeast Asia and, to some extent, in East Asia is generally high and rising (see Table 3). Susceptibility to chloramphenicol, TMP-SMZ, and ampicillin in South Asia is rebounding. In Southeast Asia, MDR strains remain predominant, and some acquired resistance to fluoroquinolones by the early 2000s.

The most recent professional guideline for the treatment of typhoid fever in south Asia was issued by the Indian Association of Pediatrics (IAP) in October 2006. Although these guidelines were published for pediatric typhoid fever, the authors feel that they are also applicable to adult cases. For empiric treatment of uncomplicated typhoid fever, the IAP recommends cefixime and, as a second-line agent, azithromycin. For complicated typhoid fever, they recommend ceftriaxone. Aztreonam and imipenem are second-line agents for complicated cases.[57] The authors believe that the IAP recommendations apply to empiric treatments of typhoid fever in both adults and children.

In high-prevalence areas outside the areas discussed above, the rate of intermediate sensitivity or resistance to fluoroquinolones is 3.7% in the Americas (P =.132), 4.7% (P =.144) in sub-Saharan Africa, and 10.8% (P =.706) in the Middle East. Therefore, for strains that originate outside of south or Southeast Asia, the WHO recommendations may still be valid—that uncomplicated disease should be treated empirically with oral ciprofloxacin and complicated typhoid fever from these regions should be treated with intravenous ciprofloxacin.[49, 52, 58, 25, 59]

Resistance in the United States

In the United States in 2012, 68% of S typhi isolates and 95% of S paratyphi isolates were fully resistant to nalidixic acid. While full resistance to ciprofloxacin was considerably less, intermediate susceptibilities to ciprofloxacin in both organisms closely matched resistance to nalidixic acid. Note that nalidixic acid is a nontherapeutic drug that is used outside of the United States as a stand-in for fluoroquinolones in sensitivity assays. In the United States, it is still used specifically for S typhi infection.[49, 23]

The rate of multidrug resistance in 2012 was 9% in S typhi and 0% in S paratyphi. (Multidrug-resistant S typhi is, by definition, resistant to the original first-line agents, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole.)

There have been no cases of ceftriaxone-resistant S typhi or S paratyphi documented in the United States, at least since 2003.[60]

Antibiotic resistance is a moving target. Reports are quickly outdated, and surveys of resistance may have limited geographic scope. Therefore, any recommendation regarding antibiotic treatment must be taken with a grain of salt. However, in the authors' opinion, if the origin of the infection is unknown, the combination of a first-generation fluoroquinolone and a third-generation cephalosporin should be used. This allows for most effective clearance if the organism is fluoroquinolone-susceptible but still covers strains that are not.

Ceftriaxone and azithromycin continue to be effective against most isolates of S typhi and S paratyphi, although resistance to ceftriaxone appears to be increasing, especially in extensively drug-resistant (XDR) strain of S typhi identified in Pakistan in 2016.[61] This variant continues to remain sensitive to azithromycin and to the carbapenems.

Antibiotic treatment of typhoid fever

Severe or complicated infections

For infections that are not acquired in Pakistan, ceftriaxone should be started empirically. In this setting, resistance to ceftriaxone is unusual. In cases that do not originate in southern Asia, a fluoroquinolone should be considered because of its potential advantage of hastening defervesce then is achievable by cephalosporins.

For infections that are acquired in Pakistan, a carbapenem should be administered because of the risk of XDR strains.

Mild or uncomplicated infections

In less-severe uncomplicated infections, it is appropriate to begin oral therapy. Unless the risk of fluoroquinolone resistance is significant, ciprofloxacin or ofloxacin is preferred. Azithromycin offers dual advantages of low risk of resistance and excellent oral absorption.

Because of the risk of developing antibiotic resistance, the concept of using dual antibiotic therapy has been revived. In addition, some evidence shows that the clinical course is improved with such combinations. Specifically, the combination of cefixime-ofloxacin has been approved by the Indian Regulatory Authority for the treatment of typhoid fever.[62]

Table 3. Antibiotic Recommendations by Origin and Severity



First-Line Antibiotics

Second-Line Antibiotics

South Asia, East Asia[57]

[63, 50]


Cefixime PO

Azithromycin PO


Ceftriaxone IV or

Cefotaxime IV

Aztreonam IV or

Imipenem IV

Eastern Europe, Middle East, sub-Saharan Africa, South America[58, 64]


Ciprofloxacin PO or

Ofloxacin PO

Cefixime PO or

Amoxicillin PO or


or Azithromycin PO


Ciprofloxacin IV or

Ofloxacin IV

Ceftriaxone IV or

Cefotaxime IV or

Ampicillin IV



Unknown geographic origin or Southeast Asia[65, 57]

[63, 50, 58, 64]


Cefixime PO plus

Ciprofloxacin PO or

Ofloxacin PO

Azithromycin PO*


Ceftriaxone IV or

Cefotaxime IV, plus

Ciprofloxacin IV or

Ofloxacin IV

Aztreonam IV or

Imipenem IV, plus

Ciprofloxacin IV


Ofloxacin IV

*Note that the combination of azithromycin and fluoroquinolones is not recommended because it may cause QT prolongation and is relatively contraindicated.

Future directions

A meta-analysis found that azithromycin appeared to be superior to fluoroquinolones and ceftriaxone with lower rates of clinical failure and relapse respectively. Although the data did not permit firm conclusions, if further studies confirm the trend, azithromycin could become a first-line treatment.[66]

Chloramphenicol (Chloromycetin)

Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria. Since its introduction in 1948, has proven to be remarkably effective for enteric fever worldwide. For sensitive strains, still most widely used antibiotic to treat typhoid fever. In the 1960s, S typh i strains with plasmid-mediated resistance to chloramphenicol began to appear and later became widespread in many endemic countries of the Americas and Southeast Asia, highlighting need for alternative agents.

Produces rapid improvement in patient's general condition, followed by defervescence in 3-5 d. Reduced preantibiotic-era case-fatality rates from 10%-15% to 1%-4%. Cures approximately 90% of patients. Administered PO unless patient is nauseous or experiencing diarrhea; in such cases, IV route should be used initially. IM route should be avoided because it may result in unsatisfactory blood levels, delaying defervescence.

Amoxicillin (Trimox, Amoxil, Biomox)

Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. At least as effective as chloramphenicol in rapidity of defervescence and relapse rate. Convalescence carriage occurs less commonly than with other agents when organisms are fully susceptible. Usually given PO with a daily dose of 75-100 mg/kg tid for 14 d.

Trimethoprim and sulfamethoxazole (Bactrim DS, Septra)

Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa. As effective as chloramphenicol in defervescence and relapse rate. Trimethoprim alone has been effective in small groups of patients.

Ciprofloxacin (Cipro)

Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared. Proven to be highly effective for typhoid and paratyphoid fevers. Defervescence occurs in 3-5 d, and convalescent carriage and relapses are rare. Other quinolones (eg, ofloxacin, norfloxacin, pefloxacin) usually are effective. If vomiting or diarrhea is present, should be given IV. Fluoroquinolones are highly effective against multiresistant strains and have intracellular antibacterial activity.

Not currently recommended for use in children and pregnant women because of observed potential for causing cartilage damage in growing animals. However, arthropathy has not been reported in children following use of nalidixic acid (an earlier quinolone known to produce similar joint damage in young animals) or in children with cystic fibrosis, despite high-dose treatment.

Cefotaxime (Claforan)

Arrests bacterial cell wall synthesis, which inhibits bacterial growth. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms. Excellent in vitro activity against S typhi and other salmonellae and has acceptable efficacy in typhoid fever. Only IV formulations are available. Recently, emergence of domestically acquired ceftriaxone-resistant Salmonella infections has been described.

Azithromycin (Zithromax)

Treats mild to moderate microbial infections. Administered PO at 10 mg/kg/d (not exceeding 500 mg), appears to be effective to treat uncomplicated typhoid fever in children 4-17 y. Confirmation of these results could provide an alternative for treatment of typhoid fever in children in developing countries, where medical resources are scarce.

Ceftriaxone (Rocephin)

Third-generation cephalosporin with broad-spectrum gram-negative activity against gram-positive organisms; Excellent in vitro activity against S typhi and other salmonellae.

Levofloxacin (Levaquin)

For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.


Class Summary

Dexamethasone may decrease the likelihood of mortality in severe typhoid fever cases complicated by delirium, obtundation, stupor, coma, or shock if bacterial meningitis has been definitively ruled out by cerebrospinal fluid studies. To date, the most systematic trial of this has been a randomized controlled study in patients aged 3-56 years with severe typhoid fever who were receiving chloramphenicol therapy. This study compared outcomes in 18 patients given placebo with outcomes in 20 patients given dexamethasone 3 mg/kg IV over 30 minutes followed by dexamethasone 1 mg/kg every 6 hours for 8 doses. The fatality rate in the dexamethasone arm was 10% versus 55.6% in the placebo arm (P =.003).[67]

Nonetheless, this point is still debated. A 2003 WHO statement endorsed the use of steroids as described above, but reviews by eminent authors in the New England Journal of Medicine (2002)[4] and the British Medical Journal (2006)[68] do not refer to steroids at all. A 1991 trial compared patients treated with 12 doses of dexamethasone 400 mg or 100 mg to a retrospective cohort in whom steroids were not administered. This trial found no difference in outcomes among the groups.[69]

The data are sparse, but the authors of this article agree with the WHO that dexamethasone should be used in cases of severe typhoid fever.

Dexamethasone (Decadron)

Prompt administration of high-dose dexamethasone reduces mortality in patients with severe typhoid fever without increasing incidence of complications, carrier states, or relapse among survivors.



Further Outpatient Care

After discharge, patients should be monitored for relapse or complications for 3 months after treatment has commenced.

Five percent to 10% of patients treated with antibiotics experience relapse of typhoid fever after initial recovery. Relapses typically occur approximately 1 week after therapy is discontinued, but relapse after 70 days has been reported. In these cases, the blood culture results are again positive, and high serum levels of H, O, and Vi antibodies and rose spots may reappear.

A relapse of typhoid fever is generally milder and of shorter duration than the initial illness. In rare cases, second or even third relapses occur. Notably, the relapse rate is much lower following treatment with the new quinolone drugs, which have effective intracellular penetration.

S typhi and S paratyphi rarely develop antibiotic resistance during treatment. If an antibiotic has been chosen according to sensitivities, relapse should dictate a search for anatomic, pathologic, or genetic predispositions rather than for an alternate antibiotic.

Previous infection does not confer immunity. In any suspected relapse, infection with a different strain should be ruled out.

Depending on the antibiotic used, between 0% and 5.9% of treated patients become chronic carriers. In some cases, the organism evades antibiotics by sequestering itself within gallstones or Schistosoma haematobium organisms that are infecting the bladder. From there, it is shed in stool or urine, respectively. If present, these diseases must be cured before the bacterium can be eliminated.

Untreated survivors of typhoid fever may shed the bacterium in the feces for up to 3 months. Therefore, after disease resolution, 3 stool cultures in one-month intervals should be performed to rule out a carrier state. Concurrent urinary cultures should be considered.

Further Inpatient Care

If treated with well-selected antibiotics, patients with typhoid fever (enteric fever) should defervesce within 3-5 days. However, patients with complicated typhoid fever should finish their course intravenously and should remain in the hospital if unable to manage this at home.

Patients with complicated typhoid fever should be admitted through the acute phase of the illness. Uncomplicated cases are generally treated on an outpatient basis unless the patient is a public health risk or cannot be fully monitored outside the home.


Travelers to endemic countries should avoid raw unpeeled fruits or vegetables since they may have been prepared with contaminated water and should not buy food from street vendors; in addition, they should drink only boiled water.

In endemic countries, the most cost-effective strategy for reducing the incidence of typhoid fever is the institution of public health measures to ensure safe drinking water and sanitary disposal of excreta. The effects of these measures are long-term and reduce the incidence of other enteric infections, which are a major cause of morbidity and mortality in those areas.


In endemic areas, mass immunization with typhoid vaccines at regular intervals considerably reduces the incidence of infections.

Routine typhoid vaccination is not recommended in the United States but is indicated for travelers to endemic areas, persons with intimate exposure to a documented S typhi carrier (eg, household contacts of chronic carriers, defined as persons with excretion of S typhi in urine or stool ≥1 year), and microbiology laboratory personnel who frequently work with S typhi. In their 2015 recommendations, the Advisory Committee on Immunization Practices in the US recommends that travelers to countries with a high prevalence of typhoid and recognized risk for exposure to Styphi should be vaccinated against typhoid, even if they are staying with friends or relatives or only traveling for a short time.[70]

Vaccines are not approved for use in children younger than 2 years. The efficacy of typhoid fever vaccinations against paratyphi serovars has not been firmly established, but is markedly less than their efficacy against typhi.[71]

Travelers should be vaccinated at least one week prior to departing for an endemic area. Because typhoid vaccines lose effectiveness after several years, consultation with a specialist in travel medicine is advised if the individual is traveling several years after vaccination. In addition, clinicians should warn travelers to consume only safe foods and beverages, because typhoid vaccines offer only moderate protection, and large inocula of S t yphi can overcome vaccine-induced protection.

The only absolute contraindication to vaccination is a history of severe local or systemic reactions following a previous dose. The typhoid vaccines available in the United States have not been studied in pregnant women.

Currently, the 3 typhoid fever vaccines include injected Vi capsular polysaccharide (ViCPS; Typhim Vi, Pasteur Merieux) antigen, enteric Ty21a (Vivotif Berna, Swiss Serum and Vaccine Institute) live-attenuated vaccine, and an acetone-inactivated parenteral vaccine (used only in members of the armed forces). The efficacy of both vaccines available to the general public approaches 50%.

Vi capsular polysaccharide antigen vaccine

Vi capsular polysaccharide antigen vaccine is composed of purified Vi antigen, the capsular polysaccharide elaborated by S typhi isolated from blood cultures. The Vi antigen is absent in S paratyphi A, but this vaccine does provide some in vitro immunogenicity against S paratyphi A. This may be due to trace amounts of other, common antigens in the preparation.[72]

Primary vaccination with ViCPS consists of a single parenteral dose of 0.5 mL (25 µg IM) one week before travel. The vaccine manufacturer does not recommend the vaccine for children younger than 2 years. Booster doses are needed every 2 years to maintain protection if continued or renewed exposure is expected.

Adverse effects include fever, headache, erythema, and/or induration of 1 cm or greater. In a study conducted in Nepal, the ViCPS vaccine produced fewer local and systemic reactions than the control (the 23-valent pneumococcal vaccine).[73] Among school children in South Africa, ViCPS produced less erythema and induration than the control (bivalent vaccine).

A systemic review and meta-analysis of 5 randomized controlled trials on the efficacy and safety of ViCPS versus placebo or nontyphoid vaccine found a cumulative efficacy of 55% (95% CI, 30%-70%).

The efficacy of vaccination with ViCPS has not been studied among persons from areas without endemic disease who travel to endemic regions or among children younger than 5 years. ViCPS has not been given to children younger than 1 year.

Questions concerning Vi typhoid vaccine effectiveness in young children (ie, < 5 y) have inhibited its use in developing countries. Whether the vaccine is effective under programmatic conditions is also unclear.

Sur et al conducted a phase IV effectiveness trial in slum-dwelling residents aged 2 years or older in India to determine vaccine protection. Participants (n=37,673) were randomly assigned to receive a single dose of either Vi vaccine or inactivated hepatitis A vaccine, according to geographic clusters. The mean rate of Vi vaccine coverage was 61% and 60% for the hepatitis A vaccine.

Typhoid fever was diagnosed in 96 subjects in the hepatitis A vaccine group compared with 34 in the Vi vaccine group (no more than 1 episode was reported per individual). Protective effect for typhoid with the Vi vaccine was 61% (P< 0.001) compared with the hepatitis A vaccine group. Children vaccinated while aged 2-5 years had an 80% protection level. Unvaccinated members of the Vi vaccine clusters showed a protection level of 44%. The overall protection level with all Vi vaccine cluster residents was 57%. The authors concluded that the Vi vaccine was effective in young children and protected unvaccinated neighbors of Vi vaccinees.[74]


Ty21a is an oral vaccine that contains live attenuated S typhi Ty21a strains in an enteric-coated capsule. The vaccine elicits both serum and intestinal antibodies and cell-mediated immune responses.

In the United States, primary vaccination with Ty21a consists of one enteric-coated capsule taken on alternate days to a total of 4 capsules. The capsules must be refrigerated (not frozen), and all 4 doses must be taken to achieve maximum efficacy.

The optimal booster schedule has not been determined; however, the longest reported follow-up study of vaccine trial subjects indicated that efficacy continued for 5 years after vaccination. The manufacturer recommends revaccination with the entire 4-dose series every 5 years if continued or renewed exposure to S typhi is expected. This vaccine may be inactivated if given within 3 days of antibiotics.

Adverse effects are rare. They include abdominal discomfort, nausea, vomiting, fever, headache, and rash or urticaria.

The vaccine manufacturer of Ty21a recommends against use in children younger than 6 years. It should not be administered to immunocompromised persons; the parenteral vaccines present theoretically safer alternatives for this group.

A systemic review and meta-analysis of 4 randomized controlled trials on the efficacy and safety of Ty21a versus placebo or nontyphoid vaccine found a cumulative efficacy of 51% (95% CI, 36%-62%).

The efficacy of Ty21a has not been studied among persons from areas without endemic disease who travel to disease-endemic regions.

Acetone-inactivated parenteral vaccine

Acetone-inactivated parenteral vaccine is currently available only to members of the US Armed Forces. Efficacy rates for this vaccine range from 75%-94%. Booster doses should be administered every 3 years if continued or renewed exposure is expected.

The parenteral heat-phenol–inactivated vaccine (Wyeth-Ayerst) has been discontinued.

No information has been reported concerning the use of one vaccine as a booster after primary vaccination with a different vaccine. However, using either the series of 4 doses of Ty21a or 1 dose of ViCPS for persons previously vaccinated with parenteral vaccine is a reasonable alternative to administration of a booster dose of parenteral inactivated vaccine.

A more effective vaccine is on the horizon. Vi polysaccharide-tetanus typhoid conjugate vaccine (TCV) is a combination of the 1 polysaccharide antigen and tetanus toxoid. It appears to be more immunogenic and longer acting other typhoid vaccines.[75]

Targeted use of vaccines in areas of the world with high rates of typhoid fever and/or resistant Salmonella isolates makes economic sense in reducing the disease burden and associated costs.[76]


In the past 2 decades, reports from disease-endemic areas have documented a wide spectrum of neuropsychiatric manifestations of typhoid fever. Potential neuropsychiatric manifestations of typhoid fever include the following:

  • A toxic confusional state, characterized by disorientation, delirium, and restlessness, is characteristic of late-stage typhoid fever. In some cases, these and other neuropsychiatric features dominate the clinical picture at an early stage.

  • Facial twitching or convulsions may be the presenting feature. Meningismus is not uncommon, but frank meningitis is rare. Encephalomyelitis may develop, and the underlying pathology may be that of demyelinating leukoencephalopathy. In rare cases, transverse myelitis, polyneuropathy, or cranial mononeuropathy develops.

  • Stupor, obtundation, or coma indicates severe disease.

  • Focal intracranial infections are uncommon, but multiple brain abscesses have been reported.[77]

  • Other less-common neuropsychiatric manifestations events have included spastic paraplegia, peripheral or cranial neuritis, Guillain-Barré syndrome, schizophrenialike illness, mania, and depression.

Respiratory complications may include the following:

  • Cough

  • Ulceration of posterior pharynx

  • Occasional presentation as acute lobar pneumonia (pneumotyphoid)

Cardiovascular complications may include the following:

  • Nonspecific electrocardiographic changes occur in 10%-15% of patients with typhoid fever.

  • Toxic myocarditis occurs in 1%-5% of persons with typhoid fever and is a significant cause of death in endemic countries. Toxic myocarditis occurs in patients who are severely ill and toxemic and is characterized by tachycardia, weak pulse and heart sounds, hypotension, and electrocardiographic abnormalities.

  • Pericarditis is rare, but peripheral vascular collapse without other cardiac findings is increasingly described. Pulmonary manifestations have also been reported in patients with typhoid fever.[78]

Hepatobiliary complications may include the following:

  • Mild elevation of transaminases without symptoms is common in persons with typhoid fever.

  • Jaundice may occur in persons with typhoid fever and may be due to hepatitis, cholangitis, cholecystitis, or hemolysis.

  • Pancreatitis and accompanying acute renal failure and hepatitis with hepatomegaly have been reported.[79]

Intestinal manifestations may include the following:

  • The 2 most common complications of typhoid fever include intestinal hemorrhage (12% in one British series) and perforation (3%-4.6% of hospitalized patients).

  • From 1884-1909 (ie, preantibiotic era), the mortality rate in patients with intestinal perforation due to typhoid fever was 66%-90% but is now significantly lower. Approximately 75% of patients have guarding, rebound tenderness, and rigidity, particularly in the right lower quadrant.

  • Diagnosis is particularly difficult in the approximately 25% of patients with perforation and peritonitis who do not have the classic physical findings. In many cases, the discovery of free intra-abdominal fluid is the only sign of perforation.

Genitourinary manifestations may include the following:

  • Approximately 25% of patients with typhoid fever excrete S typhi in their urine at some point during their illness.

  • Immune complex glomerulitis[80] and proteinuria have been reported, and IgM, C3 antigen, and S typhi antigen can be demonstrated in the glomerular capillary wall.

  • Nephritic syndrome may complicate chronic S typhi bacteremia associated with urinary schistosomiasis.

  • Nephrotic syndrome may occur transiently in patients with glucose-6-phosphate dehydrogenase deficiency.

  • Cystitis: Typhoid cystitis is very rare. Retention of urine in the typhoid state may facilitate infection with coliforms or other contaminants.

Hematologic manifestations may include the following:

  • Subclinical disseminated intravascular coagulation is common in persons with typhoid fever.

  • Hemolytic-uremic syndrome is rare.[81]

  • Hemolysis may also be associated with glucose-6-phosphate dehydrogenase deficiency.

Musculoskeletal and joint manifestations may include the following:

  • Skeletal muscle characteristically shows Zenker degeneration, particularly affecting the abdominal wall and thigh muscles.

  • Clinically evident polymyositis may occur.[82]

  • Arthritis is very rare and most often affects the hip, knee, or ankle.

Late sequelae (rare in untreated patients and exceedingly rare in treated patients) may include the following:

  • Neurologic - Polyneuritis, paranoid psychosis, or catatonia[83]

  • Cardiovascular - Thrombophlebitis of lower-extremity veins

  • Genitourinary -Orchitis

  • Musculoskeletal - Periostitis, often abscesses of the tibia and ribs; spinal abscess (typhoid spine; very rare)


The prognosis among persons with typhoid fever depends primarily on the speed of diagnosis and initiation of correct treatment. Generally, untreated typhoid fever carries a mortality rate of 15%-30%. In properly treated disease, the mortality rate is less than 1%.

An unspecified number of patients experience long-term or permanent complications, including neuropsychiatric symptoms and high rates of gastrointestinal cancers.[84]

Patient Education

Because vigilant hand hygiene, vaccination, and the avoidance of risky foods and beverages are mainstays of prevention, educating travelers before they enter a disease-endemic region is important.

Because the protection offered by vaccination is at best partial, close attention to personal, food, and water hygiene should be maintained. The US Centers for Disease Control and Prevention dictum to "boil it, cook it, peel it, or forget it" is a good rule in any circumstance. If disease occurs while abroad despite these precautions, one can usually call the US consulate for a list of recommended doctors.

For excellent patient education resources, see eMedicineHealth's patient education article Foreign Travel.

Case study

A wealthy middle-aged man presented to his physician a few days after the onset of flulike symptoms, including fever, myalgias, chills, severe abdominal pain, and a cough, in addition to severe abdominal pain. Over the next 2 weeks, he lost a great deal of weight. He had intermittent but ever-increasing fevers. About 3 weeks after the onset of symptoms, he developed a few pale, salmon-colored macules on his trunk. His cough became much more frequent and severe. He became delirious, listlessly wandering around the house fiddling with doorknobs. During the fourth week of his illness, he rapidly declined with increasing somnolence. After nearly 4 weeks of illness, he died surrounded by his loving family.

The patient was Prince Albert, the Consort to Queen Victoria. He was diagnosed with typhoid fever. His personal physician, Sir William Jenner, a leading expert on the disease, diagnosed typhoid fever. Prince Albert received the best therapy of the day.

For the most up-to-date information, visit the Centers for Disease Control and Prevention Travelers' Health Typhoid resource (www.cdc.gov/travel) or call the Travelers' Health automated information line at 877-FYI-TRIP. The World Health Organization’s site (www.who.int/ith), International Society of Travel Medicine site (www.istm.org), and Travel Doctor (www.traveldoctor.co.uk/diseases.htm) contain useful information as well, though the authors disagree with some of the WHO’s antibiotic guidelines.


Questions & Answers


What is typhoid fever (enteric fever)?

What is the classic presentation of typhoid fever (enteric fever)?

What is the history of Salmonella typhi (S typhi), and what is the origin of the term typhoid fever?

What is the difference between paratyphoid fever and typhoid fever (enteric fever)?

What is the difference between nontyphoidal salmonellae and S typhi or S paratyphi?

Why does Salmonella typhi (S typhi) have greater infectivity than related serovars?

What is the pathophysiology of Salmonella typhi (S typhi) infection?

How long does Salmonella typhi (S typhi) survive in asymptomatic carriers?

What size inoculum is needed for Salmonella typhi (S typhi) or S paratyphi to cause typhoid fever (enteric fever)?

How is Salmonella typhi (S typhi) transmitted?

How is Salmonella paratyphi (S paratyphi) transmitted?

Who is most at risk for Salmonella paratyphi (S paratyphi) infection?

How does decreased stomach acidity affect the risk of Salmonella typhi (S typhi) infection?

Are individuals with HIV/AIDS at increased risk of Salmonella typhi (S typhi) or S paratyphi infection?

Which genes increase or decrease the risk of typhoid fever (enteric fever)?

In which demographic has there been a recent increase in typhoid fever (enteric fever)?

What is the incidence of typhoid fever (enteric fever) in the US?

What is the global prevalence of typhoid fever (enteric fever)?

What is the mortality rate for treated and untreated typhoid fever (enteric fever)?

Does typhoid fever (enteric fever) have a racial predilection?

Is typhoid fever (enteric fever) more common in men or women?

Is typhoid fever (enteric fever) more common among specific age groups?


When should typhoid fever (enteric fever) be suspected?

What are the first signs of typhoid fever (enteric fever)?

Which symptoms develop during the first two weeks of typhoid fever (enteric fever)?

How does typhoid fever (enteric fever) progress in the third week?

What is the clinical course of typhoid fever (enteric fever) after 3 weeks?

Do most cases of typhoid fever (enteric fever) follow a typical clinical course?

Can typhoid fever (enteric fever) cause diarrhea?

What are atypical presentations of typhoid fever (enteric fever)?

How soon after treatment for typhoid fever (enteric fever) does the disease remit?

Which bacteria cause typhoid fever (enteric fever)?


What are the differential diagnoses for Typhoid Fever?


Which lab tests are required for the diagnosis of typhoid fever (enteric fever)?

What is the criterion standard for diagnosis of typhoid fever (enteric fever)?

Is culture of bone marrow aspirate useful in the diagnosis of typhoid fever (enteric fever)?

Are blood, intestinal secretions, or stool culture useful in the detection of Salmonella typhi (S typhi) in suspected typhoid fever (enteric fever)?

Are stool culture, urine culture, and cultures of rose spots useful in the detection of Salmonella typhi (S typhi) in suspected typhoid fever (enteric fever)?

Which techniques are used for bone marrow aspiration and blood culture in the diagnosis of typhoid fever (enteric fever)?

Is polymerase chain reaction (PCR) useful in the diagnosis of typhoid fever (enteric fever)?

What specific serologic tests are used in the diagnosis of typhoid fever (enteric fever)?

What nonspecific lab results are common in typhoid fever (enteric fever)?

When are imaging studies warranted in the evaluation of typhoid fever (enteric fever)?

What is the most sensitive method of isolating Salmonella typhi (S typhi)?

What is the typical histologic finding in typhoid fever (enteric fever)?

During the course of typhoid fever (enteric fever), which pathologic stages occur in the intestines?

What are the histologic findings of typhoid fever (enteric fever) outside the intestines?

How is complicated typhoid fever (enteric fever) characterized and how is it treated differently from uncomplicated typhoid fever?


Should treatment begin before a diagnosis of typhoid fever (enteric fever) is confirmed?

When can patients with typhoid fever (enteric fever) be treated on an outpatient basis?

Is contact isolation needed in patients hospitalized with typhoid fever (enteric fever)?

When is surgery indicated in typhoid fever (enteric fever)?

Which specialists should be consulted in typhoid fever (enteric fever)?

What are the dietary restrictions in typhoid fever (enteric fever)?

Should physical activity be limited in typhoid fever (enteric fever)?


How common is relapse after treatment for typhoid fever (enteric fever)?

How intense are relapses of typhoid fever (enteric fever)?

Are there antibiotic-resistant strains of Salmonella typhi (S typhi) or S paratyphi?

Does previous infection confer immunity to typhoid fever (enteric fever)?

How often do patients treated for typhoid fever (enteric fever) become chronic carriers of Salmonella typhi (S typhi) or S paratyphi?

For how long should patients with typhoid fever (enteric fever) be hospitalized?

What steps can travelers to endemic areas take to reduce the risk of contracting typhoid fever (enteric fever)?

Is routine vaccination against typhoid fever (enteric fever) recommended in the US?

When should typhoid fever (enteric fever) vaccine be given to individuals traveling to an endemic area?

Are there contraindications to typhoid fever (enteric fever) vaccination?

Which typhoid fever (enteric fever) vaccinations are available?

What is in the Vi capsular polysaccharide (ViCPS) antigen vaccine used in the prevention of typhoid fever (enteric fever)?

What is the dosage of Vi capsular polysaccharide (ViCPS) antigen vaccine used in the prevention of typhoid fever (enteric fever)?

What are potential adverse effects of Vi capsular polysaccharide (ViCPS) antigen vaccine used in the prevention of typhoid fever (enteric fever)?

What is the efficacy of Vi capsular polysaccharide (ViCPS) antigen vaccine used in the prevention of typhoid fever (enteric fever)?

What is in the Ty21a vaccine used in the prevention of typhoid fever (enteric fever)?

What is the dosage of Ty21a vaccine used in the prevention of typhoid fever (enteric fever)?

What are potential adverse effects of Ty21a vaccine used in the prevention of typhoid fever (enteric fever)?

What is the efficacy of Ty21a vaccine used in the prevention of typhoid fever (enteric fever)?

Is the acetone-inactivated parenteral vaccine used in the prevention of typhoid fever (enteric fever) available to the general public?

What are the neuropsychiatric complications of typhoid fever (enteric fever)?

What are respiratory complications of typhoid fever (enteric fever)?

What are cardiovascular complications of typhoid fever (enteric fever)?

What are hepatobiliary complications of typhoid fever (enteric fever)?

What are intestinal complications of typhoid fever (enteric fever)?

What are genitourinary complications of typhoid fever (enteric fever)?

What are hematologic complications of typhoid fever (enteric fever)?

What are musculoskeletal and joint complications of typhoid fever (enteric fever)?

What are late sequelae of typhoid fever (enteric fever)?

What is the prognosis of typhoid fever (enteric fever)?

What education should be given to travelers before they enter regions where typhoid fever (enteric fever) is endemic?

What organizations provide up-to-date information on typhoid fever (enteric fever)?


Which medications in the drug class Antibiotics are used in the treatment of Typhoid Fever?

Which medications in the drug class Corticosteroids are used in the treatment of Typhoid Fever?